June 2001
Worldwide Biotech;Jun2001, Vol. 13 Issue 6, p4
Trade Publication
Reports on the acquisition of Covance Biotechnology Services Inc. by the pharmaceutical firm Diosynth of the Akzo Nobel company of the Netherlands.


Related Articles

  • COMPANY NEWS.  // Life Science Today;Dec2001, Vol. 2 Issue 6, p6 

    Reports on the developments concerning the pharmaceutical and biotechnology industries as of December 2001. Introduction of hot water purification systems; Introduction of a web-based strategy to improve business and production; Automation system for the production of active pharmaceutical...

  • Partnerships Pull Biotechnology Into Mainstream Therapeutics. Mullin, Rick // Chemical Week;6/19/2002, Vol. 164 Issue 25, p61 

    Reports that companies in the pharmaceutical and fine chemicals industry have announced partnerships to develop biopharmaceutical products at the Biotechnology Industry Organization's BIO 2002 trade show in Toronto, Canada. Terms of the deal between Dow Chemical and Epicyte; Information on the...

  • Diosynth Expands its API Toolbox. Scott, Alex // Chemical Week;3/19/2003, Vol. 165 Issue 11, p40 

    Reports the expansion of the active pharmaceutical ingredients (API) toolbox of Akzo Nobel subsidiary Diosynth in 2003. Information on Diosynth's API synthesis operations; Description of market conditions in 2002; Sales in the biotechnology area.

  • Diosynth Introduces High-Speed Peptides Process. Scott, Alex // Chemical Week;4/30/2003, Vol. 165 Issue 16, p23 

    Reports that Diosynth, Akzo Nobel's active pharmaceutical ingredients subsidiary, developed a novel high-speed process for commercial production of synthetic peptides. Description of solid-phase peptide production; Information on how pharmaceutical peptides are formed; Advantages of peptides.

  • Custom Players See Increased Biotech Demand. Milmo, Sean // Chemical Market Reporter;04/30/2001, Vol. 259 Issue 18, p8 

    Discusses the increase in the demand for contract services due to the preference of pharmaceutical and biotechnology companies to outsource instead of invest in production facilities. Acquisition of Biotechnology Services Inc. by Diosynth; Requirement set by drug licensing authorities regarding...

  • Diosysnth Secures Long-Term Supply Deal with Pfizer. Scott, Alex // Chemical Week;6/11/2003, Vol. 165 Issue 21, p27 

    Reports on the long-term contract signed by Diosynth with Pfizer to produce commercial quantities of an active pharmaceutical ingredient for Pfizer's growth hormone disorder drug Somavert. Benefits of the contract to Diosynth; Involvement of the biotechnology subsidiary of the company in...

  • Diosynth Slashes Plant Capacity as Demand Shrinks. Scott, Alex // Chemical Week;2/25/2004, Vol. 166 Issue 7, p27 

    Reports on the decision of Diosynth, the custom manufacturing subsidiary of Akzo Nobel, to close its pharma intermediates and raw materials plant in Mexico City and to scale-back capacity in its Buckhaven, Great Britain intermediates plant and active pharma intermediates (API) facilities in...

  • Akzo Braces for More Cuts as Diosynth.  // Chemical Market Reporter;2/9/2004, Vol. 265 Issue 6, p6 

    Reports on the continued restructuring plans for Akzo Nobel BV in Europe. Possibility of dismissing employees from the manufacturing division Diosynth BV; Result of lower demand for chemical and biotechnology products; Expectation of divestiture of chemical activities in catalysts, coating,...

  • pharmaceuticals & fine chemicals.  // Chemical Week;2/16/2005, Vol. 167 Issue 6, p22 

    Presents updates on the pharmaceutical and chemical industries as of February 16, 2005. Background on a deal between biotechnology firm Pharming and Diosynth; Percentage of increase in the annual funding proposed by the administration of U.S. President George W. Bush for the U.S. Office of Drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics